Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function – implications for the adoptive immunotherapy of leukaemia
- 1 December 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 126 (3) , 403-411
- https://doi.org/10.1046/j.1365-2249.2001.01692.x
Abstract
Evidence of an immune mediated graft-versus-leukaemia effect has led to the belief that T and NK cell based adoptive immunotherapy can constitute effective treatment for relapsed leukaemias. However, work on solid tumours has shown this strategy may be hampered, by an immune escape mechanism in which tumour secreted immunosuppressive factors compromise T and NK cell function. Indeed, acute myeloid leukaemia (AML) cells secrete immunosuppressive factors that block the synthesis of Th1 type cytokines in T cells. We demonstrate here that this immunosuppression, mediated by both HL60 AML cell line and primary AML blasts, inhibits T and NK cell proliferation but not cytolytic activity. Supernatants from HL60 cell line and primary AML blasts inhibited T cell proliferation to mitogenic and alloantigen stimulation but had no effect on cytolytic function. Similarly, the proliferation of NK cells to IL-2 and IL-15 stimulation was inhibited whilst their cytolytic function, shown by lysis of AML blasts, K562 and Daudi cells remained unaffected. The failure of T and NK cells to proliferate was not due to effector cell apoptosis. Indeed, removal of lymphocytes from the immunosuppressive environment partially restored their capacity to respond to mitogenic stimulation. T cells exposed to immunosuppressive supernatants did not increase expression of mitotic inhibitory proteins that arrest cell division, thereby ruling this out as a mechanism of operation for this immunosuppression. T cell expansion requires antigen stimulation, usually provided in the form of AML blasts, therefore our data suggest that NK cells may be more practical for the immunotherapy of AML.Keywords
This publication has 50 references indexed in Scilit:
- CML vaccines as a paradigm of the specific immunotherapy of cancerBlood Reviews, 2000
- Tumor-Induced Immunosuppression: A Barrier to Immunotherapy of Large Tumors by Cytokine-Secreting Tumor VaccineHuman Gene Therapy, 2000
- How do cytotoxic lymphocytes kill their targets?Current Opinion in Immunology, 1998
- The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemiaBone Marrow Transplantation, 1997
- Transforming Growth Factor Beta 1 is Significantly Elevated in Plasma of Patients Suffering from Renal Cell CarcinomaCytokine, 1996
- The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C.The Journal of Experimental Medicine, 1996
- Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia.The Journal of Experimental Medicine, 1992
- Loss of natural killer activity as an indicator of relapse in acute leukaemiaClinical and Experimental Immunology, 1990
- Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effectBritish Journal of Haematology, 1988
- Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.The Journal of Experimental Medicine, 1987